Niagen Bioscience price to sales ratio NAGE

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 1.5×
10-year median: 5.0×
Against its 10-year history: 9th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.2× to 15.5×
Peer median: 1.9×

Niagen Bioscience's price to sales ratio is 1.5× as of Oct 23, 2026.

That is below its ten-year median of 5.0×, lower than on 91% of days in the last ten years.

Over that time it ranged from 1.2× in Oct 2023 to 15.5× in Dec 2017.

The median for 4 chemicals stocks of a similar size is 1.9×.

Price to sales ratio over time

median 5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.5×	1.5×	4.2×
2025	4.2×	4.1×	10.4×
2024	4.6×	1.3×	6.4×
2023	1.3×	1.2×	2.4×
2022	1.8×	1.2×	3.5×
2021	3.9×	3.9×	15.1×
2020	5.2×	3.5×	7.1×
2019	6.3×	4.1×	8.2×
2018	6.2×	5.5×	14.1×
2017	13.2×	3.2×	15.5×
2016	4.9×	3.3×	8.7×
2015	6.1×	5.7×	10.7×
2014	13.9×	13.5×	19.1×
2013	14.9×	5.1×	14.9×
2012	5.2×	5.2×	11.1×

Against its peers

Companies in Chemicals nearest Niagen Bioscience's size, closest first, today.

Company	Price to sales ratio
NAGENiagen Bioscience	1.5×
FTLFFitlife Brands	0.8×
FTKFlotek Industries	3.0×
BTMDbiote	0.2×
CRONCronos	6.9×
Peer median	1.9×

Where Niagen Bioscience ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Niagen Bioscience

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.